Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect

Irrespective of age, patients with aggressive Waldenstrom macroglobulinemia (WM) who have exhausted chemo-immunotherapy-based approaches may be candidates for allogeneic hematopoietic cell transplantation (HCT), a strategy that has been rarely attempted.[1][1]–[7][2] In Seattle, conditioning with

[1]  P. Hari,et al.  Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  H. Deeg,et al.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Pascutto,et al.  Risk of second cancers in Waldenström macroglobulinemia. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. LaCasce,et al.  Long-term complications of lymphoma and its treatment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Schmitz,et al.  Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Blaise,et al.  Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire , 2010, Haematologica.

[7]  J. Gribben,et al.  The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study , 2008, Hematology.

[8]  J. Lipton,et al.  Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience , 2007, Bone Marrow Transplantation.

[9]  H. Goldschmidt,et al.  Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  J. Radich,et al.  Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2004, Blood.

[11]  J. Perrier,et al.  Transplantation in Waldenstrom's macroglobulinemia--the French experience. , 2003, Seminars in oncology.

[12]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[13]  H. Deeg,et al.  DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. , 1995, Blood.

[14]  H. Deeg,et al.  DLA-identical bone marrow grafts after low-dose total body irradiation: the effect of canine recombinant hematopoietic growth factors. , 1994, Blood.